Last reviewed · How we verify
MPSV4
MPSV4 is a meningococcal polysaccharide conjugate vaccine that stimulates immune responses against multiple serogroups of Neisseria meningitidis.
MPSV4 is a meningococcal polysaccharide conjugate vaccine that stimulates immune responses against multiple serogroups of Neisseria meningitidis. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
At a glance
| Generic name | MPSV4 |
|---|---|
| Sponsor | CanSino Biologics Inc. |
| Drug class | Meningococcal conjugate vaccine |
| Target | Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
MPSV4 contains polysaccharide antigens from meningococcal serogroups A, C, W, and Y conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent responses. The vaccine triggers both humoral and cellular immunity to prevent invasive meningococcal disease caused by these serogroups. This conjugate approach provides improved immunological memory compared to unconjugated polysaccharide vaccines.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
Common side effects
- Injection site pain or erythema
- Fever
- Myalgia
- Headache
Key clinical trials
- A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds (PHASE3)
- A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds (PHASE3)
- National Vaccine Adverse Event Reporting Survey and Etiology
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MPSV4 CI brief — competitive landscape report
- MPSV4 updates RSS · CI watch RSS
- CanSino Biologics Inc. portfolio CI